semaglutide and ileus FDA adds warning for intestinal blockage on Novo's Ozempic These highlights do not include

PlexusDx helps you find your optimal dose without guessing

Step-by-step conversion formulas, charts, and syringe tips included.

Learn what researchers discovered, why the findings matter, and key reminders for people with type 2 diabetes concerned about brain health.

The topline of the story is that the U.S

March 17, 2026

Triple Receptor Agonism The defining characteristic of retatrutide is its simultaneous activation of three key metabolic hormone receptors: GLP-1 Receptor: Activation increases insulin secretion in a glucose-dependent manner, reduces glucagon secretion, delays gastric emptying, and decreases appetite through central nervous system effects GIP Receptor: Stimulates insulin secretion and enhances the body's response to glucose while potentially improving lipid metabolism Glucagon Receptor: Activation increases energy expenditure and lipid oxidation, which complements the anorectic effects of GLP-1 receptor activation This triple agonism approach is designed to address multiple aspects of metabolic dysfunction simultaneously, potentially offering superior efficacy compared to single or dual receptor agonists[1][2]